CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment (CORRECT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01715467 |
Recruitment Status :
Completed
First Posted : October 29, 2012
Last Update Posted : June 16, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Dupuytren's Contracture |
This is a prospective, multi-center, observational study. Patients will be recruited based on the usual care presentation at each investigative site, as regular practice would dictate. Consecutive patients deemed eligible for the study by their physician will be invited to participate during their usual care visit. Enrolled patients will receive evaluations and treatment for Dupuytren's contracture according to the standard of care and clinical practice at each study site. No study-specific visits will be required as part of the study. Treatment and Follow-up Visits will be determined by the treating physician. Treatments received for Dupuytren's contracture will be recorded (ie, XIAFLEX, fasciectomy, or fasciotomy/needle aponeurotomy), including initial treatment and any subsequent therapy. The full prescribing information and medication guide for XIAFLEX is provided in this protocol as reference (Appendix B). Patient data (including treatment outcomes, joint contracture measured by the treating physician, and evidence of recurrence) and health care resource utilization data will be drawn from the patients' medical records, examination, and patient interviews. These data will be recorded via a web-based electronic data collection (EDC) system.
PROs will be collected by self-completed questionnaires given to each patient via web-based data collection or telephone interviews. The site will follow up with the patient according to usual practice. Information from the patient's visit may include goniometry and the physician's assessment of treatment outcome and healthcare utilization. Patients will be considered enrolled in the study for a maximum of 4 years post-enrollment or until death, withdrawal of consent, loss to follow-up, or study closure.
Study Type : | Observational |
Actual Enrollment : | 162 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Community Registry Study Evaluating Dupuytren's Contracture Treatment. A Prospective, Observational, Longitudinal, Multicenter Study of the Treatment Patterns and Outcomes in Patients With Dupuytren's Contracture. |
Study Start Date : | September 2012 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

- The primary objective is to collect real-world data regarding patient reported outcomes of the 3 primary treatment modalities in patients with Dupuytren's contracture. [ Time Frame: 4 years ]
- Examine safety, effectiveness and association between treatments and selected healthcare utilization and patient report outcomes. [ Time Frame: 4 years ]
The secondary objectives are as follows:
- Examine the safety trends of various treatment options in patients with Dupuytren's contracture
- Examine the effectiveness trends of various treatment options, specifically evaluating long term contracture recurrence
- Examine the association between various treatment regimens and healthcare resource utilization
- Examine the association between various treatments and patient-reported outcomes (PROs) such as disease burden, ADLs, hand functionality, work performance, time to return to work, treatment satisfaction, and patient preference

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Women or men 18 years of age or older
- Patients with a Dupuytren's contracture of at least a single joint and a desire for correction
- Patients who are able to read and understand English
- Patients who are capable of understanding and cooperating with the requirements of the study
- Patients who are willing and able to respond to the posttreatment assessments via telephone or internet
- Patients must provide written informed consent, indicating that they understand the purpose of and requirements of the study and are willing to participate in the study.
Exclusion Criteria:
- Patients who decide not to pursue correction of the Dupuytren's contracture.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01715467

Study Director: | Urdaneta Veronica, MD | Endo Pharmaceuticals |
Responsible Party: | Endo Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01715467 |
Other Study ID Numbers: |
AUX-CC-901 |
First Posted: | October 29, 2012 Key Record Dates |
Last Update Posted: | June 16, 2015 |
Last Verified: | June 2015 |
Dupuytren Contracture Auxilium XIAFLEX |
Dupuytren Contracture Contracture Joint Diseases Musculoskeletal Diseases Muscular Diseases Fibroma |
Neoplasms, Fibrous Tissue Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Connective Tissue Diseases |